By now, we’re all (hopefully) getting accustomed to the concept of “patient-centricity.” However, another commonly overlooked but equally important group of healthcare stakeholders is careg
As the world passes the year and a half mark of the COVID-19 pandemic, the evolving ‘new normal’ experience across the healthcare sector has brought huge changes to the way pharma engages h
While the effects of COVID-19 have been devastating for many industries, its positive impact on accelerating the uptake of digital health technologies and virtual collaboration solutions is
Digital may be upending every aspect of the pharma industry, but many would assume that engagement activities like advisory boards, working groups and medical education will remain a bastio
In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing recent changes in China, England and the US and asking how pharma can work with he
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.